Applied DNA's LineaRx Subsidiary Completes Supply Chain Repositioning

Applied DNA Sciences, Inc., has announced the successful completion of a significant initiative undertaken by its subsidiary LineaRx, Inc. This shift focuses on sourcing critical input materials for LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The move aligns with the 2024 BIOSECURE Act and increasing demands for domestic supply chains within the biopharmaceutical industry.

LineaRx President, Clay D. Shorrock, highlighted the readiness of the LineaDNA platform for speed and scale with domestic sourcing. The subsidiary stands as the largest PCR-based cell-free DNA producer in the U.S. Recent advancements include the launch of GMP manufacturing services, positioning LineaRx to bolster domestic production of genetic medicines, including mRNA and DNA products, as well as cell and gene therapies.

Utilizing its proprietary PCR-based LineaDNA™ platform, LineaRx efficiently manufactures high-fidelity DNA crucial for developing genetic medicines. A robust U.S.-based supply chain is in place, representing over 75% of the manufacturing cost of goods for LineaRx. This marks a decisive step in reshoring drug development and manufacturing efforts.